Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical Pharmacy and Pharmacology | JAMA - JAMA Network
jamanetwork.comSubmitted by jamanetworkcom5065 in health
This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.